4 Results for "

hemodynamic effect

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "hemodynamic effect" in MCE Product Catalog:

Cat. No.: HY-12184
CAS No.: 211230-67-0
Purity:  98.27%
ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels .
loading...
    loading...
Cat. No.: HY-P3765
CAS No.: 91421-87-3
Target:  

Peptides

Research Areas:  

Cardiovascular Disease

Auriculin A is a synthetic atrial natriuretic factor (ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits .
loading...
    loading...
Cat. No.: HY-P10616
CAS No.: 624735-22-4
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

Salusin-α is an endogenous bioactive peptide with hemodynamic and cell proliferation activities. Salusin-α can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate, but its effect is weaker than that of Salusin-β (HY-P10617). Salusin-α has potential application value in cardiovascular disease research .
loading...
    loading...
Cat. No.: HY-121586
CAS No.: 59040-30-1
Synonyms: Bay g 6575
Target:  

Lipoxygenase

Research Areas:  

Cardiovascular Disease

Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro .
loading...
    loading...